ArkVax

London, United Kingdom · Founded 2020 · Privately Held (backing)

Developer of a glycan-based vaccine technology intended to revolutionize animal vaccinology and combat antimicrobial resistance. ArkVax is based in London, United Kingdom and was founded in 2020.

Last price · $/share
—
Implied valuation
—
Total raised
—
Last round
—

Who backs ArkVax?

6 investors
InvestorType
Future Planet CapitalVenture capital
UK Innovation & Science Seed FundVenture capital
Biotechnology and Biological Sciences Research CouncilOther
Accelerate@Babraham—
London School of Hygiene & Tropical Medicine—
Start Codon—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

ArkVax investors

6 investors are on record for ArkVax, including Future Planet Capital, UK Innovation & Science Seed Fund, Biotechnology and Biological Sciences Research Council and Accelerate@Babraham.

Free account
More of ArkVax with a free account
  • ·Watch ArkVax: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 6 firms already write checks for companies like ArkVax. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View